EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

US Clinical Practice Experience with Eculizumab in Myasthenia Gravis: Acute Clinical Events and Healthcare Resource Utilization

Richard J Nowak, Ali A Habib, Andrew J Klink, Srikanth Muppidi, Anju Parthan, S Chloe Sader, Alexandrina Balanean, Ajeet Gajra, James F Howard, ELEVATE Study Group

Drugs - Real World Outcomes · 2024-12 · 11 (4) · 593-601

DOI: 10.1007/s40801-024-00457-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drugs - Real World Outcomes, online erschienen am 29.10.2024. Verfasst von Richard J Nowak und 9 weiteren Autor:innen. Beteiligte Einrichtung: Yale University School of Medicine, New Haven, CT, USA. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCATS NIH HHS, Alexion, AstraZeneca Rare Disease.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: The terminal complement inhibitor eculizumab is approved in the USA for the treatment of patients with acetylcholine receptor antibody-positive generalized myasthenia gravis (MG). The ELEVATE study aimed to examine clinical-practice outcome data on eculizumab effectiveness in US adults with MG (generalized or ocular). This paper reports the findings on MG exacerbations and crises and associated healthcare resource utilization, and the use of rescue therapy. METHODS: A retrospective chart review was conducted of US adults with MG who initiated eculizumab. Outcomes assessed for up to 2 years before and after eculizumab initiation included percentages and rates per patient per year (PPPY) of exacerbations and crises (the latter defined as intubation/impending intubation), healthcare resource utilization, and rescue therapy administration. RESULTS: A total of 119 patients diagnosed with MG were enrolled in the study; 92 patients had ≥ 3 months of data both before and during eculizumab therapy and were included in the analyses. The mean rate of MG exacerbations decreased from 0.385 PPPY before eculizumab initiation to 0.152 PPPY during eculizumab treatment (p = 0.0034); the mean rate of MG crises decreased from 0.411 to 0.056 PPPY (p = 0.0018). Rates of healthcare resource utilization and rescue therapy use also decreased significantly during eculizumab treatment. CONCLUSIONS: This retrospective chart review analysis provides evidence for a beneficial impact of eculizumab treatment on the incidence of MG exacerbations and crises and associated healthcare resource utilization in clinical practice, and on rescue therapy use. These data further support the therapeutic benefits of eculizumab in patients with MG.

Autor:innen und Institutionen

  • Yale University School of Medicine, New Haven, CT, USA.
  • University of California, Irvine, CA, USA.
  • Cardinal Health, Dublin, OH, USA.
  • Stanford Neuroscience Health Center, Palo Alto, CA, USA.
  • Alexion, AstraZeneca Rare Disease, Boston, MA, USA.
  • FibroGen Inc., San Francisco, CA, USA.

Förderung

  • NCATS NIH HHS
  • Alexion, AstraZeneca Rare Disease

Zitieren

APA

Nowak, R. J., Habib, A. A., Klink, A. J., Muppidi, S., Parthan, A., Sader, S. C., Balanean, A., Gajra, A., Howard, J. F., & ELEVATE Study Group (2024). US Clinical Practice Experience with Eculizumab in Myasthenia Gravis: Acute Clinical Events and Healthcare Resource Utilization. Drugs - Real World Outcomes, 11(4), 593-601. https://doi.org/10.1007/s40801-024-00457-8

Vancouver

Nowak RJ, Habib AA, Klink AJ, Muppidi S, Parthan A, Sader SC, et al. US Clinical Practice Experience with Eculizumab in Myasthenia Gravis: Acute Clinical Events and Healthcare Resource Utilization. Drugs - Real World Outcomes. 2024;11(4):593-601. doi:10.1007/s40801-024-00457-8

BibTeX
@article{Nowak2024,
  author = {Nowak, Richard J and Habib, Ali A and Klink, Andrew J and Muppidi, Srikanth and Parthan, Anju and Sader, S Chloe and Balanean, Alexandrina and Gajra, Ajeet and Howard, James F and ELEVATE Study Group, ELEVATE Study Group},
  title = {US Clinical Practice Experience with Eculizumab in Myasthenia Gravis: Acute Clinical Events and Healthcare Resource Utilization},
  journal = {Drugs - Real World Outcomes},
  year = {2024},
  volume = {11},
  number = {4},
  pages = {593--601},
  doi = {10.1007/s40801-024-00457-8}
}
Kostenlos starten →